Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies - PubMed (original) (raw)
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies
K J Stittelaar et al. J Virol. 2000 May.
Abstract
Recombinant modified vaccinia virus Ankara (MVA), encoding the measles virus (MV) fusion (F) and hemagglutinin (H) (MVA-FH) glycoproteins, was evaluated in an MV vaccination-challenge model with macaques. Animals were vaccinated twice in the absence or presence of passively transferred MV-neutralizing macaque antibodies and challenged 1 year later intratracheally with wild-type MV. After the second vaccination with MVA-FH, all the animals developed MV-neutralizing antibodies and MV-specific T-cell responses. Although MVA-FH was slightly less effective in inducing MV-neutralizing antibodies in the absence of passively transferred antibodies than the currently used live attenuated vaccine, it proved to be more effective in the presence of such antibodies. All vaccinated animals were effectively protected from the challenge infection. These data suggest that MVA-FH should be further tested as an alternative to the current vaccine for infants with maternally acquired MV-neutralizing antibodies and for adults with waning vaccine-induced immunity.
Figures
FIG. 1
Expression of MV F and H glycoproteins by MVA-FH. (A) Diagram of the genome of MVA-FH. del II, deletion II; del III, deletion III; PH5, modified H5 promoter; P7.5, 7.5 promoter. (B) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of [35S]methione-labeled proteins from CEF infected with MVA-FH and immunoprecipitated with measles polyclonal antibody. MW, molecular weights of marker proteins in thousands. The positions of MV H, F0, F1, and F2 proteins are indicated.
FIG. 2
Development of VN antibody responses in plasma of macaques vaccinated at weeks 0 and 4 (indicated with arrows) with MVA-FH in the absence (group A) or in the presence (group B) of passively transferred MV-specific VN antibodies.
FIG. 3
Development of MV glycoprotein-specific plasma IgG responses in macaques vaccinated at weeks 0 and 4 (indicated with arrows) with MVA-FH in the absence (A) or in the presence (B) of passively transferred MV-specific VN antibodies. The control macaques (C) were vaccinated with MVA-wt.
FIG. 4
Development of MVA-specific plasma IgG responses. The first and second vaccinations are indicated with arrows.
FIG. 5
Development of MV glycoprotein-specific plasma IgG responses in macaques vaccinated at weeks 0 and 4 with MV-Schwarz or rVV-FH in the absence (A and B, respectively) and presence (C and D, respectively) of MV-specific VN antibodies. p.i., passively immunized; ND, not done (due to unavailability of historical plasma).
FIG. 6
MV-specific T-cell responses in PBMC bulk cultures of macaques 8 weeks after vaccination with MVA-FH in the absence (A) or presence (B) of passively transferred MV-specific VN antibodies or with MVA-wt (C). PBMC were stimulated once in vitro with autologous MV-infected mac.B-LCL cells and expanded in the presence of rhIL-2 alone or in the presence of both rhIL-2 and rhIL-4 (indicated with an asterisk). After 12 to 14 days, cells were harvested and treated with chymotrypsin to strip preexisting CD69 molecules from the membrane surface. Subsequently, cells were restimulated for 6 h with UV-inactivated autologous MV-infected mac.B-LCL cells, uninfected mac.B-LCL cells, or without mac.B-LCL cells (medium), and the membrane expression of CD3, CD8, and CD69 was determined. The percentages of CD69-positive cells in the CD3+ lymphocytes, as gated on the basis of an FSC/SSC plot, are shown for CD8+ (I) and CD8− (II) cells. ND, not done (because no cells could be expanded).
FIG. 7
Number of MV-infected cells/106 LLC (open bars) or PBMC (black bars) at different times after intratracheal challenge with 103 TCID50s of MV-BIL. Macaques had been vaccinated with MVA-FH in the absence (A) or in the presence (B) of passively transferred MV-specific VN antibodies or with MVA-wt (group C). +, time point at which MV could be reisolated from PEC.
FIG. 8
Development of MV glycoprotein-specific plasma IgG and VN antibody responses in macaques at different times after intratracheal challenge with 103 TCID50s of MV-BIL. Macaques had been vaccinated with MVA-FH in the absence (A) or in the presence (B) of passively transferred MV-specific VN antibodies or with MVA-wt (C).
FIG. 9
Development of MV-N-specific plasma IgM responses in macaques at different times after intratracheal challenge with 103 TCID50s of MV-BIL. Macaques had been vaccinated with MVA-FH in the absence (A) or in the presence (B) of passively transferred MV-specific VN antibodies or with MVA-wt (C).
Similar articles
- A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.
Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE. Pan CH, et al. J Virol. 2010 Apr;84(8):3798-807. doi: 10.1128/JVI.01566-09. Epub 2010 Feb 3. J Virol. 2010. PMID: 20130066 Free PMC article. - Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates.
Stittelaar KJ, Vos HW, van Amerongen G, Kersten GF, Osterhaus AD, de Swart RL. Stittelaar KJ, et al. Vaccine. 2002 Dec 13;21(3-4):155-7. doi: 10.1016/s0264-410x(02)00453-x. Vaccine. 2002. PMID: 12450688 - Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model.
Weidinger G, Ohlmann M, Schlereth B, Sutter G, Niewiesk S. Weidinger G, et al. Vaccine. 2001 Apr 6;19(20-22):2764-8. doi: 10.1016/s0264-410x(00)00531-4. Vaccine. 2001. PMID: 11282186 - Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine.
Osterhaus A, van Amerongen G, van Binnendijk R. Osterhaus A, et al. Vaccine. 1998 Aug-Sep;16(14-15):1479-81. doi: 10.1016/s0264-410x(98)00112-1. Vaccine. 1998. PMID: 9711792 Review. - Measles virus.
Naim HY. Naim HY. Hum Vaccin Immunother. 2015;11(1):21-6. doi: 10.4161/hv.34298. Epub 2014 Nov 1. Hum Vaccin Immunother. 2015. PMID: 25483511 Free PMC article. Review.
Cited by
- Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.
Neckermann P, Mohr M, Billmeier M, Karlas A, Boilesen DR, Thirion C, Holst PJ, Jordan I, Sandig V, Asbach B, Wagner R. Neckermann P, et al. Front Immunol. 2024 Feb 6;15:1338492. doi: 10.3389/fimmu.2024.1338492. eCollection 2024. Front Immunol. 2024. PMID: 38380318 Free PMC article. - Stability of the HSV-2 US-6 Gene in the del II, del III, CP77, and _I8R_-G1L Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells.
Atukorale VN, Weir JP, Meseda CA. Atukorale VN, et al. Vaccines (Basel). 2020 Mar 19;8(1):137. doi: 10.3390/vaccines8010137. Vaccines (Basel). 2020. PMID: 32204367 Free PMC article. - Comparative Loss-of-Function Screens Reveal ABCE1 as an Essential Cellular Host Factor for Efficient Translation of Paramyxoviridae and Pneumoviridae.
Anderson DE, Pfeffermann K, Kim SY, Sawatsky B, Pearson J, Kovtun M, Corcoran DL, Krebs Y, Sigmundsson K, Jamison SF, Yeo ZZJ, Rennick LJ, Wang LF, Talbot PJ, Duprex WP, Garcia-Blanco MA, von Messling V. Anderson DE, et al. mBio. 2019 May 14;10(3):e00826-19. doi: 10.1128/mBio.00826-19. mBio. 2019. PMID: 31088929 Free PMC article. - Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.
Alharbi NK. Alharbi NK. Hum Vaccin Immunother. 2019;15(1):203-209. doi: 10.1080/21645515.2018.1513439. Epub 2018 Sep 6. Hum Vaccin Immunother. 2019. PMID: 30148692 Free PMC article. Review. - In Vitro Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells.
Laksono BM, Grosserichter-Wagener C, de Vries RD, Langeveld SAG, Brem MD, van Dongen JJM, Katsikis PD, Koopmans MPG, van Zelm MC, de Swart RL. Laksono BM, et al. J Virol. 2018 Mar 28;92(8):e00131-18. doi: 10.1128/JVI.00131-18. Print 2018 Apr 15. J Virol. 2018. PMID: 29437964 Free PMC article.
References
- Auwaerter P G, Rota P A, Elkins W R, Adams R J, DeLozier T, Shi Y, Bellini W J, Murphy B R, Griffin D E. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis. 1999;180:950–958. - PubMed
- Clements C J, Cutts F T. The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol. 1995;191:13–33. - PubMed
- Cutts F T, Markowitz L E. Successes and failures in measles control. J Infect Dis. 1994;170(Suppl. 1):S32–S41. - PubMed
- De Swart R L, Vos H W, UytdeHaag F G C M, Osterhaus A D M E, Van Binnendijk R S. Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies in a FACS-measured immunofluorescence assay. J Virol Methods. 1998;71:35–44. - PubMed
- Earl P L, Moss B, Wyatt L S, Carroll M W. Generation of recombinant vaccinia viruses. In: Ausubel F M, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A, Struhl K, editors. Current protocols in molecular biology. New York, N.Y: Greene Publishing Associates & Wiley Interscience; 1998. pp. 16.17.1–16.17.19.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous